Literature DB >> 19259966

Medullary pain facilitating neurons mediate allodynia in headache-related pain.

Rebecca M Edelmayer1, Todd W Vanderah, Lisa Majuta, En-Tan Zhang, Beatriz Fioravanti, Milena De Felice, Juliana G Chichorro, Michael H Ossipov, Tamara King, Josephine Lai, Shashi H Kori, Andrew C Nelsen, Keri E Cannon, Mary M Heinricher, Frank Porreca.   

Abstract

OBJECTIVE: To develop and validate a model of cutaneous allodynia triggered by dural inflammation for pain associated with headaches. To explore neural mechanisms underlying cephalic and extracephalic allodynia.
METHODS: Inflammatory mediators (IM) were applied to the dura of unanesthetized rats via previously implanted cannulas, and sensory thresholds of the face and hind-paws were characterized.
RESULTS: IM elicited robust facial and hind-paw allodynia, which peaked within 3 hours. These effects were reminiscent of cutaneous allodynia seen in patients with migraine or other primary headache conditions, and were reversed by agents used clinically in the treatment of migraine, including sumatriptan, naproxen, and a calcitonin gene-related peptide antagonist. Consistent with clinical observations, the allodynia was unaffected by a neurokinin-1 antagonist. Having established facial and hind-paw allodynia as a useful animal surrogate of headache-associated allodynia, we next showed that blocking pain-facilitating processes in the rostral ventromedial medulla (RVM) interfered with its expression. Bupivacaine, destruction of putative pain-facilitating neurons, or block of cholecystokinin receptors prevented or significantly attenuated IM-induced allodynia. Electrophysiological studies confirmed activation of pain-facilitating RVM "on" cells and transient suppression of RVM "off" cells after IM.
INTERPRETATION: Facial and hind-paw allodynia associated with dural stimulation is a useful surrogate of pain associated with primary headache including migraine and may be exploited mechanistically for development of novel therapeutic strategies for headache pain. The data also demonstrate the requirement for activation of descending facilitation from the RVM for the expression of cranial and extracranial cutaneous allodynia, and are consistent with a brainstem generator of allodynia associated with headache disorders.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19259966      PMCID: PMC2772103          DOI: 10.1002/ana.21537

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  35 in total

1.  Inhibition of neuropathic pain by selective ablation of brainstem medullary cells expressing the mu-opioid receptor.

Authors:  F Porreca; S E Burgess; L R Gardell; T W Vanderah; T P Malan; M H Ossipov; D A Lappi; J Lai
Journal:  J Neurosci       Date:  2001-07-15       Impact factor: 6.167

2.  Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model.

Authors:  Hayrunnisa Bolay; Uwe Reuter; Andrew K Dunn; Zhihong Huang; David A Boas; Michael A Moskowitz
Journal:  Nat Med       Date:  2002-02       Impact factor: 53.440

3.  An association between migraine and cutaneous allodynia.

Authors:  R Burstein; D Yarnitsky; I Goor-Aryeh; B J Ransil; Z H Bajwa
Journal:  Ann Neurol       Date:  2000-05       Impact factor: 10.422

4.  The periaqueductal grey matter modulates trigeminovascular input: a role in migraine?

Authors:  Y E Knight; P J Goadsby
Journal:  Neuroscience       Date:  2001       Impact factor: 3.590

5.  A neurohistochemical blueprint for pain-induced loss of appetite.

Authors:  A Malick; M Jakubowski; J K Elmquist; C B Saper; R Burstein
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-14       Impact factor: 11.205

6.  Lanepitant, an NK-1 antagonist, in migraine prevention.

Authors:  D J Goldstein; W W Offen; E G Klein; L A Phebus; P Hipskind; K W Johnson; R E Ryan
Journal:  Cephalalgia       Date:  2001-03       Impact factor: 6.292

7.  Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine.

Authors:  T W Ho; L K Mannix; X Fan; C Assaid; C Furtek; C J Jones; C R Lines; A M Rapoport
Journal:  Neurology       Date:  2007-10-03       Impact factor: 9.910

8.  Defeating migraine pain with triptans: a race against the development of cutaneous allodynia.

Authors:  Rami Burstein; Beth Collins; Moshe Jakubowski
Journal:  Ann Neurol       Date:  2004-01       Impact factor: 10.422

9.  Analgesic triptan action in an animal model of intracranial pain: a race against the development of central sensitization.

Authors:  Rami Burstein; Moshe Jakubowski
Journal:  Ann Neurol       Date:  2004-01       Impact factor: 10.422

Review 10.  Chronic pain and medullary descending facilitation.

Authors:  Frank Porreca; Michael H Ossipov; G F Gebhart
Journal:  Trends Neurosci       Date:  2002-06       Impact factor: 13.837

View more
  88 in total

1.  Physiological basis for inhibition of morphine and improgan antinociception by CC12, a P450 epoxygenase inhibitor.

Authors:  Mary M Heinricher; Jennifer J Maire; Delaina Lee; Julia W Nalwalk; Lindsay B Hough
Journal:  J Neurophysiol       Date:  2010-10-06       Impact factor: 2.714

2.  Ionic mechanisms underlying inflammatory mediator-induced sensitization of dural afferents.

Authors:  Andrea H Vaughn; Michael S Gold
Journal:  J Neurosci       Date:  2010-06-09       Impact factor: 6.167

Review 3.  Diencephalic and brainstem mechanisms in migraine.

Authors:  Simon Akerman; Philip R Holland; Peter J Goadsby
Journal:  Nat Rev Neurosci       Date:  2011-09-20       Impact factor: 34.870

Review 4.  Update on medication-overuse headache.

Authors:  Milena De Felice; Michael H Ossipov; Frank Porreca
Journal:  Curr Pain Headache Rep       Date:  2011-02

5.  pH-evoked dural afferent signaling is mediated by ASIC3 and is sensitized by mast cell mediators.

Authors:  Jin Yan; Xiaomei Wei; Christina Bischoff; Rebecca M Edelmayer; Gregory Dussor
Journal:  Headache       Date:  2013-06-28       Impact factor: 5.887

6.  Sex differences in the inflammatory mediator-induced sensitization of dural afferents.

Authors:  N N Scheff; M S Gold
Journal:  J Neurophysiol       Date:  2011-07-13       Impact factor: 2.714

7.  Dural afferents express acid-sensing ion channels: a role for decreased meningeal pH in migraine headache.

Authors:  Jin Yan; Rebecca M Edelmayer; Xiaomei Wei; Milena De Felice; Frank Porreca; Gregory Dussor
Journal:  Pain       Date:  2010-10-23       Impact factor: 6.961

8.  Effects of systemic inhibitors of acid-sensing ion channels 1 (ASIC1) against acute and chronic mechanical allodynia in a rodent model of migraine.

Authors:  Clément Verkest; Emilie Piquet; Sylvie Diochot; Mélodie Dauvois; Michel Lanteri-Minet; Eric Lingueglia; Anne Baron
Journal:  Br J Pharmacol       Date:  2018-09-22       Impact factor: 8.739

9.  Sustained morphine-induced sensitization and loss of diffuse noxious inhibitory controls in dura-sensitive medullary dorsal horn neurons.

Authors:  Akiko Okada-Ogawa; Frank Porreca; Ian D Meng
Journal:  J Neurosci       Date:  2009-12-16       Impact factor: 6.167

Review 10.  Does sumatriptan cross the blood-brain barrier in animals and man?

Authors:  Peer Carsten Tfelt-Hansen
Journal:  J Headache Pain       Date:  2009-12-10       Impact factor: 7.277

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.